Veru (NASDAQ:VERU) Stock Rating Lowered by Wall Street Zen

Veru (NASDAQ:VERU) was downgraded by equities researchers at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research note issued on Saturday, Wall Street Zen reports.

VERU has been the subject of several other research reports. Weiss Ratings cut Veru from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 16th. Westpark Capital began coverage on shares of Veru in a report on Tuesday, October 6th. They issued a “buy” rating on the stock. Finally, Oppenheimer restated an “outperform” rating on shares of Veru in a report on Wednesday, October 14th. Three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $24.50.

Veru Price Performance

Shares of VERU stock opened at $2.19 on Friday. The firm has a market cap of $37.34 million, a P/E ratio of -3.17 and a beta of -1.20. The company has a 50 day moving average of $2.46 and a 200-day moving average of $2.50. Veru has a 12-month low of $2.05 and a 12-month high of $7.33.

Veru (NASDAQ:VERU) last posted its earnings results on Monday, August 10th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.02. As a group, equities analysts expect that Veru will post -1.04 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Royal Bank of Canada grew its holdings in Veru by 69.3% during the 1st quarter. Royal Bank of Canada now owns 12,239 shares of the company’s stock worth $27,000 after acquiring an additional 5,008 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in Veru in the first quarter worth about $153,000. Finally, FNY Investment Advisers LLC acquired a new position in Veru during the 2nd quarter valued at approximately $328,000. Institutional investors own 47.16% of the company’s stock.

About Veru

Veru Inc is a biopharmaceutical company focused on developing medicines for oncology and metabolic diseases. The company’s pipeline includes therapies intended to address cancer-related muscle wasting, obesity, and other conditions associated with the loss of lean body mass and physical function.

Veru’s principal investigational product is enobosarm, an oral selective androgen receptor modulator being studied for its potential to preserve or increase muscle mass and improve physical function in patients with cancer-related wasting and obesity.